Clinical trials recruiting for Castration-resistant Prostate Cancer
15
Recruiting trials
24
US states with sites
6
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Apalutamide | 3 |
| 161Tb RAD402 | 1 |
| Abiraterone | 1 |
| Carotuximab | 1 |
| DCC-2812 | 1 |
| Darolutamide | 1 |
| Degarelix | 1 |
| Enzalutamide | 1 |
| Goserelin | 1 |
| Histrelin | 1 |
| IDE034 | 1 |
| Injection, 161Tb-SibuDAB, Dose Escalation | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Tennessee | 4 |
| California | 3 |
| Michigan | 3 |
| Texas | 3 |
| Utah | 3 |
| Virginia | 3 |
| Colorado | 2 |
| Florida | 2 |
| Missouri | 2 |
| New York | 2 |
| North Carolina | 2 |
| Pennsylvania | 2 |
Top cities
Nashville, Tennessee 4Austin, Texas 2Fairfax, Virginia 2Los Angeles, California 2San Antonio, Texas 2St Louis, Missouri 2West Valley City, Utah 2Ann Arbor, Michigan 1Baltimore, Maryland 1Boston, Massachusetts 1
Self-screener
Recruiting trials
- A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC
- ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
- Bipolar Androgen Therapy + Carboplatin in mCRPC
- Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
- GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
- Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer
- Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone
- Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
- Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
- Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
- Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study
Related conditions
Trials recruiting for Castration-resistant Prostate Cancer often also study these conditions. Each links to its own recruiting-trial list.
Prostate cancer 1234Prostate Adenocarcinoma 52Oligoprogressive 7Urothelial Carcinoma 29Triple-negative breast cancer 138Renal cell carcinoma 28Recurrent Prostate Cancer 9Prostate Cancer Metastatic 27Prostate Cancer (Adenocarcinoma) 43Non-small cell lung cancer 507
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Castration-resistant Prostate Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.